Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2023 Aug:131:107331.
doi: 10.1016/j.leukres.2023.107331. Epub 2023 May 29.

Outcomes with molecularly targeted agents as salvage therapy following frontline venetoclax + hypomethylating agent in adults with acute myeloid leukemia: A multicenter retrospective analysis

Vishesh Khanna  1 , Tali Azenkot  2 , Selina Qiuying Liu  3 , Jason Gilbert  4 , Edna Cheung  5 , Kimberly Lau  5 , Daniel A Pollyea  4 , Elie Traer  3 , Brian A Jonas  6 , Tian Y Zhang  1 , Gabriel N Mannis  7
Affiliations
Multicenter Study

Outcomes with molecularly targeted agents as salvage therapy following frontline venetoclax + hypomethylating agent in adults with acute myeloid leukemia: A multicenter retrospective analysis

Vishesh Khanna et al. Leuk Res. 2023 Aug.
No abstract available

Keywords: AML; Acute myeloid leukemia; Enasidenib; Gilteritinib; HMA; Hypomethylating agents; Ivosidenib; Outcomes; Targeted therapies; Venetoclax.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest VK, TA, SL, JG, EC, and KL report no conflicts of interest. BAJ: Consultant/advisor for AbbVie, BMS, Daiichi Sankyo, Genentech, Gilead, GlycoMimetics, Jazz, Kymera, Pfizer, Rigel, Servier, and Takeda; protocol steering committee for GlycoMimetics; data monitoring committee for Gilead; travel reimbursement/support from AbbVie and Rigel; institutional research funding from AbbVie, Amgen, Aptose, AROG, BMS, Celgene, Daiichi Sankyo, F. Hoffmann-La Roche, Forma, Forty-Seven, Genentech/Roche, Gilead, GlycoMimetics, Hanmi, Immune-Onc, Incyte, Jazz, Loxo Oncology, Pfizer, Pharmacyclics, Sigma Tau, and Treadwell. DAP: Consultant for Abbvie, BMS, and Rigel; research funding from Abbvie. ET: Consultant/advisor for Abbvie, Astellas, Daiichi-Sankyo, and Servier; research funding from Prelude Therapeutics, Schrodinger, Incyte, and Astra-Zeneca. TZ: Consultant: Abbvie and Servier. Research funding: BMS. GNM: Research funding: Forty Seven, Jazz, Astex, Glycomimetics, Gilead, ImmuneOnc, Syndax. Consultancy: Stemline, Pfizer, Macrogenics, Genentech, BMS/Celgene, Astellas, Agios, Abbvie, and Servier.

Comment on

MeSH terms

Substances

LinkOut - more resources